Clinical Trial Search

Primary: Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.59 units on a scale — p=<0.0001

Primary: Narcotic Dosage

Primary: Area Under the Curve (AUC) of Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Over a 1-hour Cat Allergen Exposure From Pre-challenge at Week 16 — 15.03…

Primary: Mean Difference in Body Weight Change Between Participants Assigned to Metformin and Participants Assigned to Placebo — -1.0; -3.0 kilograms

Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 48 Hours. One-Stage Activated Partial Thromboplastin Time (aPTT) -Based Assay Performed at Central…

Primary: Success Rate — 47.2; 15.4 percentage of participant — p=<0.001

Primary: Mean Time to Itch Relief — 13.36 minutes

Primary: Pain Intensity at Day 15 — 4.85 cm

Primary: Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 — 2.6; 0.8 mmHg (millimeters of mercury)

Primary: % Dropout — 21.5; 16.3 percentage of participants

Primary: Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes) — 7.4; 6.7; 8.5; 7.5 units on a scale

Primary: Postinfarct Remodeling — 11; 6 Number of participants with remodeling

Primary: Change From Baseline in Total Positive and Negative Syndrome Scale (PANSS) Score — 83.99; 53.70 scores on a scale

Primary: Integrated Clinical Global Impression of Change (I-CGI-C) at Week 12 — 2.826; 2.824 Score on a scale

Primary: 7-day Point Prevalence of Abstinence — 45; 22; 50 Participants